May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]
Read more
March 6, 2019 — FDA Commissioner Scott Gottlieb, M.D., recently stated that he was not leaving the FDA, so news of his departure at the end of the month sent shock waves through FDA-regulated industry yesterday. Citing a need to spend more time with his family, Gottlieb tweeted that he is “immensely grateful for the […]
Read more
Nov. 30, 2018 – The 2018 midterm elections resulted in a divided Congress, questions about possible agency changes, and uncertainty related to drug pricing policy and the Affordable Care Act, according to Kate Rawson, senior editor, Prevision Policy and The RPM Report, who spoke at the Coalition for Healthcare Communication’s “2018 Post-election Conference on Healthcare […]
Read more
May 29, 2018 – As the dust settles on the Trump administration’s drug pricing blueprint, the pharmaceutical industry is facing a mixed bag of potential short- and long-term impacts, according to Kate Rawson, Senior Editor, Prevision Policy and The RPM Report. Rawson, who spoke May 23 at the Coalition for Healthcare Communication Rising Leaders Conference […]
Read more